Literature DB >> 25385187

Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Takashi Taniguchi1, Yoshihide Asano, Kaname Akamata, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Maria Trojanowska, Shinichi Sato.   

Abstract

OBJECTIVE: Fli-1, a potential predisposing factor for systemic sclerosis (SSc), is constitutively down-regulated in the lesional skin of patients with SSc by an epigenetic mechanism. To investigate the impact of Fli-1 deficiency on the induction of an SSc phenotype in various cell types, we generated bleomycin-induced skin fibrosis in Fli-1(+/-) mice and investigated the molecular mechanisms underlying its phenotypic alterations.
METHODS: Messenger RNA (mRNA) levels and protein expression of target molecules were examined by quantitative reverse transcription-polymerase chain reaction and immunostaining. Transforming growth factor β (TGFβ) bioassay was used to evaluate the activation of latent TGFβ. The binding of Fli-1 to the target gene promoters was assessed with chromatin immunoprecipitation.
RESULTS: Bleomycin induced more severe dermal fibrosis in Fli-1(+/-) mice than in wild-type mice. Fli-1 haploinsufficiency activated dermal fibroblasts via the up-regulation of αvβ3 and αvβ5 integrins and activation of latent TGFβ. Dermal fibrosis in Fli-1(+/-) mice was also attributable to endothelial-to-mesenchymal transition, which is directly induced by Fli-1 deficiency and amplified by bleomycin. Th2/Th17-skewed inflammation and increased infiltration of mast cells and macrophages were seen, partly due to the altered expression of cell adhesion molecules in endothelial cells as well as the induction of the skin chemokines. Fli-1(+/-) mouse macrophages preferentially differentiated into an M2 phenotype upon stimulation with interleukin-4 (IL-4) or IL-13.
CONCLUSION: Our findings provide strong evidence for the fundamental role of Fli-1 deficiency in inducing SSc-like phenotypic alterations in dermal fibroblasts, endothelial cells, and macrophages in a manner consistent with human disease.
Copyright © 2015 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25385187      PMCID: PMC4342755          DOI: 10.1002/art.38948

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  48 in total

1.  Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway.

Authors:  J Czuwara-Ladykowska; F Shirasaki; P Jackers; D K Watson; M Trojanowska
Journal:  J Biol Chem       Date:  2001-03-16       Impact factor: 5.157

2.  Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy.

Authors:  Akane Kizu; Damian Medici; Raghu Kalluri
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

4.  Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains.

Authors:  T Yamamoto; M Kuroda; K Nishioka
Journal:  Arch Dermatol Res       Date:  2000-11       Impact factor: 3.017

5.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

6.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

7.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation.

Authors:  Yoshihide Asano; Joanna Czuwara; Maria Trojanowska
Journal:  J Biol Chem       Date:  2007-09-19       Impact factor: 5.157

9.  Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta.

Authors:  Yoshihide Asano; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2009-01-21       Impact factor: 4.272

10.  Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin.

Authors:  Yoshihide Asano; Margaret Markiewicz; Masahide Kubo; Gabor Szalai; Dennis K Watson; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

View more
  27 in total

Review 1.  Update on macrophages and innate immunity in scleroderma.

Authors:  Jennifer J Chia; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 2.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

3.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 4.  Matrix remodeling in systemic sclerosis.

Authors:  Andrew Leask
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

5.  Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5+/- ;Fli-1+/- Mice.

Authors:  Kouki Nakamura; Takashi Taniguchi; Megumi Hirabayashi; Takashi Yamashita; Ryosuke Saigusa; Shunsuke Miura; Takehiro Takahashi; Tetsuo Toyama; Yohei Ichimura; Ayumi Yoshizaki; Maria Trojanowska; Katsuhito Fujiu; Ryozo Nagai; Shinichi Sato; Yoshihide Asano
Journal:  Arthritis Rheumatol       Date:  2020-10-30       Impact factor: 10.995

6.  Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.

Authors:  Takashi Yamashita; Yoshihide Asano; Takashi Taniguchi; Kouki Nakamura; Ryosuke Saigusa; Shunsuke Miura; Tetsuo Toyama; Takehiro Takahashi; Yohei Ichimura; Ayumi Yoshizaki; Maria Trojanowska; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2016-10-21       Impact factor: 8.551

7.  RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.

Authors:  Chenming Sun; Shi-You Chen
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

8.  Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model.

Authors:  Qing Qi; Yueping Mao; Yongzhen Tian; Ke Zhu; Xushan Cha; Minghua Wu; Xiaodong Zhou
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 9.  Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.

Authors:  Benjamin Korman
Journal:  Transl Res       Date:  2019-02-23       Impact factor: 7.012

10.  Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.

Authors:  Ryosuke Saigusa; Yoshihide Asano; Takashi Taniguchi; Takashi Yamashita; Yohei Ichimura; Takehiro Takahashi; Tetsuo Toyama; Ayumi Yoshizaki; Koji Sugawara; Daisuke Tsuruta; Tadatsugu Taniguchi; Shinichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.